Cargando…

Value of serum miR-21, HE4 and CA125 in surveillance for postoperative recurrent or metastatic ovarian cancer

OBJECTIVES: To study the value of serum miR21, human epididymal secretory protein 4 (HE4) and carbohydrate antigen 125 (CA125) in the surveillance for postoperative recurrent or metastatic ovarian cancer. METHODS: A total of 169 patients diagnosed with ovarian conditions in Luanzhou Hospital of Trad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Zhenying, Han, Sugui, Zhang, Chunlei, Zhao, Honghuan, Xu, Jinxia, Sun, Xing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Professional Medical Publications 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121976/ https://www.ncbi.nlm.nih.gov/pubmed/35634597 http://dx.doi.org/10.12669/pjms.38.4.5158

Ejemplares similares

HE4, CA-125, and cystic ovarian mass
por: Wiwanitkit, Viroj
Publicado: (2012)

Urine CA125 and HE4 for the Detection of Ovarian Cancer in Symptomatic Women
por: Barr, Chloe E., et al.
Publicado: (2023)

The added value of CA125, HE4, and CA72-4 as markers for ovarian endometriosis diagnosis
por: Micu, Romeo, et al.
Publicado: (2023)

The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer
por: WEI, SU, et al.
Publicado: (2016)

Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses
por: Pitta, Denise da Rocha, et al.
Publicado: (2013)

Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women
por: Cho, Hye Yon, et al.
Publicado: (2015)

The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer
por: Zheng, Li-e, et al.
Publicado: (2016)

Are ROMA and HE4 More Accurate than CA-125, in Predicting of Ovarian Epithelial Carcinoma?
por: Behnamfar, Fariba, et al.
Publicado: (2023)

The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer
por: Anastasi, Emanuela, et al.
Publicado: (2013)

Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma
por: Quan, Quan, et al.
Publicado: (2021)

Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass
por: Partheen, Karolina, et al.
Publicado: (2011)

HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
por: Van Gorp, T, et al.
Publicado: (2011)

Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response
por: Hamed, Elham O, et al.
Publicado: (2013)

Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review
por: Dochez, Vincent, et al.
Publicado: (2019)

Predicting value of HE4 and CA125 markers for optimal cytoreductive surgery in ovarian cancer patients
por: Saffarieh, Elham, et al.
Publicado: (2022)

The value of serum HE4 and CA125 levels for monitoring the recurrence and risk stratification of endometrial endometrioid carcinoma
por: Gong, Sainan, et al.
Publicado: (2023)

A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients
por: Leandersson, Pia, et al.
Publicado: (2020)

Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women
por: Gentry-Maharaj, Aleksandra, et al.
Publicado: (2020)

The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4
por: Han, Kyung Hee, et al.
Publicado: (2019)

Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer
por: Rong, Yan, et al.
Publicado: (2021)

Correlation of Molecular Tumor Markers CA125, HE4, and CEA with the Development and Progression of Epithelial Ovarian Cancer
por: Wan, Qiuhua, et al.
Publicado: (2021)

Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer
por: Alegría-Baños, Jorge A., et al.
Publicado: (2021)

The Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population
por: Barr, Chloe E., et al.
Publicado: (2022)

Diagnostic value of CA125, HE4, and systemic immune-inflammation index in the preoperative investigation of ovarian masses
por: Song, Liyun, et al.
Publicado: (2023)

Tubo-ovarian mass with raised CA-125 in a 21-year-old female
por: Purwar, Roli, et al.
Publicado: (2022)

Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer
por: Furrer, Daniela, et al.
Publicado: (2019)

M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients
por: Będkowska, Grażyna Ewa, et al.
Publicado: (2015)

Multivariate Index Assay Is Superior to CA125 and HE4 Testing in Detection of Ovarian Malignancy in African-American Women
por: Dunton, Charles, et al.
Publicado: (2019)

Correlation analysis and clinical significance of CA125, HE4, DDI, and FDP in type II epithelial ovarian cancer
por: Qiao, Li, et al.
Publicado: (2020)

A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses
por: Anton, Cristina, et al.
Publicado: (2012)

HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases
por: Molina, Rafael, et al.
Publicado: (2011)

Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125
por: Chudecka-Głaz, Anita, et al.
Publicado: (2016)

Suitability assessment of baseline concentration of MMP3, TIMP3, HE4 and CA125 in the serum of patients with ovarian cancer
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2018)

Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam
por: Huy, Nguyen Vu Quoc, et al.
Publicado: (2018)

Assessment of Diagnostic Values among CA-125, RMI, HE4, and ROMA for Cancer Prediction in Women with Nonfunctional Ovarian Cysts
por: Oranratanaphan, Shina, et al.
Publicado: (2018)

Diagnostic Performance of F-18 FDG PET/CT Compared with CA125, HE4, and ROMA for Epithelial Ovarian Cancer
por: Lee, Sun Seong, et al.
Publicado: (2021)

VCAM-1 complements CA-125 in detecting recurrent ovarian cancer
por: Song, Jin, et al.
Publicado: (2023)

CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages
por: Wang, Zhiheng, et al.
Publicado: (2019)

Meigs’ syndrome with elevated CA-125 and HE-4: a case of luteinized fibrothecoma
por: Danilos, Jaroslaw, et al.
Publicado: (2015)

Urine CA125 and HE4 for the Triage of Symptomatic Women with Suspected Endometrial Cancer
por: Njoku, Kelechi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lpq347pll13aqkvqg2914cpekf